Strategies to reverse melanoma-induced T-cell dysfunction

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 251-256

  Fourcade, Julien ^a   Zarour, Hassane M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; HLA ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DOSE ESCALATION; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; MELANOMA; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84876731038     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.010     Document Type: Article

References (59)

1. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
2. Boon T., Coulie P.G., Van den Eynde B.J., et al. Human T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
3. Rosenberg S.A., Sherry R.M., Morton K.E., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005, 175:6169-6176.
4. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
5. Gajewski T.F., Meng Y., Blank C., et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006, 213:131-145.
6. Stewart T.J., Smyth M.J. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011, 30:125-140.
7. Odorizzi P.M., Wherry E.J. Inhibitory receptors on lymphocytes: insights from infections. J Immunol 2012, 188:2957-2965.
8. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-618.
9. Zeng G., Li Y., El-Gamil M., et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002, 62:3630-3635.
10. Quigley M., Pereyra F., Nilsson B., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010, 16:1147-1151.
11. Ahmadzadeh M., Johnson L.A., Heemskerk B., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
12. Gajewski T.F. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007, 13:5256-5261.
13. Fourcade J., Sun Z., Benallaoua M., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
14. Blank C., Brown I., Peterson A.C., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64:1140-1145.
15. Iwai Y., Ishida M., Tanaka Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297.
16. Chambers C.A., Kuhns M.S., Egen J.G., et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001, 19:565-594.
17. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-618.
18. Wolchok J.D., Neyns B., Linette G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
19. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
20. Wolchok J.D., Hoos A., O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
21. Blank C., Kuball J., Voelkl S., et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006, 119:317-327.
22. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4:336-347.
23. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
24. Okazaki T., Iwai Y., Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 2002, 14:779-782.
25. Sharpe A.H., Wherry E.J., Ahmed R., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007, 8:239-245.
26. Dong H., Zhu G., Tamada K., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
27. Tseng S.Y., Otsuji M., Gorski K., et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193:839-846.
28. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
29. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
30. Fourcade J., Kudela P., Sun Z., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009, 182:5240-5249.
31. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
32. Sznol M., Powderly J.D., Smith D.C., et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010, 28:15s. (Suppl.; abstr 2506).
33. Gadiot J., Hooijkaas A.I., Kaiser A.D., et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011, 117:2192-2201.
34. Hino R., Kabashima K., Kato Y., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116:1757-1766.
35. Taube J.M., Anders R.A., Young G.D., et al. Colocalization of inflammatory response with b7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127ra137.
36. Krieg C., Boyman O., Fu Y.X., et al. B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat Immunol 2007, 8:162-171.
37. Derre L., Rivals J.P., Jandus C., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010, 120:157-167.
38. Hemon P., Jean-Louis F., Ramgolam K., et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011, 186:5173-5183.
39. Zhu C., Anderson A.C., Schubart A., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
40. Sabatos C.A., Chakravarti S., Cha E., et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003, 4:1102-1110.
41. Sanchez-Fueyo A., Tian J., Picarella D., et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003, 4:1093-1101.
42. Kageshita T., Kashio Y., Yamauchi A., et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002, 99:809-816.
43. Baitsch L., Baumgaertner P., Devevre E., et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J Clin Invest 2011, 121:2350-2360.
44. Fourcade J., Sun Z., Pagliano O., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012, 72:887-896.
45. Curran M.A., Montalvo W., Yagita H., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
46. Fourcade J., Sun Z., Benallaoua M., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
47. Sakuishi K., Apetoh L., Sullivan J.M., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
48. Matsuzaki J., Gnjatic S., Mhawech-Fauceglia P., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010, 107:7875-7880.
49. Mattei S., Colombo M.P., Melani C., Silvani A., Parmiani G., Herlyn M. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994, 56:853-857.
50. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161.
51. Thomas D.A., Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
52. Mahipal A., Terai M., Berd D., et al. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother 2011, 60:1039-1045.
53. Yue F.Y., Dummer R., Geertsen R., et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997, 71:630-637.
54. Kurte M., Lopez M., Aguirre A., et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 2004, 173:1731-1737.
55. Chen Q., Daniel V., Maher D.W., et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 1994, 56:755-760.
56. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
57. Morgan R., Gao G., Pawling J., et al. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol 2004, 173:7200-7208.
58. Demotte N., Stroobant V., Courtoy P.J., et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008, 28:414-424.
59. Demotte N., Wieers G., Van Der Smissen P., et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 2010, 70:7476-7488.